ecancermedicalscience

Research

Clinical characteristics and first-line palliative treatment patterns in 3,414 patients with advanced lung cancer in India

6 Mar 2025
Mehak Trikha, Vanita Noronha, Minit Shah, Vijay Patil, Nandini Menon, Ajaykumar Singh, Pratik Chandrani, Omshree Shetty, Rajiv Kumar Kaushal, Trupti Pai, Amit Janu, Nilendu Purandare, Kumar Prabhash

Lung cancer, particularly non-small-cell lung cancer (NSCLC), is a major global health issue. In India, the complexity of managing this disease is heightened by diverse demographics, varying healthcare access and evolving epidemiological trends influenced by factors such as smoking and advancements in diagnostics. This study explores cancer demographics and first-line palliative treatment options. We conducted a retrospective analysis of 3,414 advanced lung cancer patients planned for palliative systemic therapy at our centre between March 2000 and June 2017. The mean age of the cohort was 56.7 interquartile range (IQR: 21–88) years with a male predominance (71.9%). Histological subtypes included adenocarcinoma (82.9%), squamous cell carcinoma (13.6%) and others (3.5%). Intrathoracic metastases were seen in 40.7% and intrathoracic and extrathoracic in 37.7% of patients. The extrathoracic sites were skeletal (32.5%), liver (14.4%), brain (13.7%) and adrenal gland (9.0%). The baseline Eastern Cooperative Oncology Group Performance status was 0 (8.3%), 1 (58.7%), 2 (20.7%), 3 (11.7%) and 4 in 0.6% of the patients. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positivity rates were lower in smokers. Most patients (92.4%) received the first-line systemic therapy, predominantly platinum-based doublets (67.1%). Tyrosine kinase inhibitors were given to 51.8% of EGFR+, 48% of ALK+ and 54.1% of mutation-negative cases. This study provides crucial insights into lung cancer demographics and treatment patterns at a single tertiary care centre in India, highlighting an increase in female lung cancer cases, steady smoking rates and improved access to genetic testing and targeted therapies.

Related Articles

Jessica O Esangbedo, Rachael O Oduyemi, Damilare Aduroja, Yetunde O Tola, Olajumoke Dele-Alonge, Emmanuel O Adesuyi, Michael O Ajiboye, Oluwadamilare Akingbade
Francisca Quintanilla, Álvaro Torres, Monserrat Villar, Catalina Muñoz, José Lizama, Bárbara Mena
Olatunde Olaniyi Abiodun Oluwafemi, Eberechukwu Uchime Kasiemobi, Mustapha Babatunde, Bankole Kofi Adedeji, Oyelayo Oluwaseun Olaoluwa, Ismaheel Aderogba Azeez, Ezekpo Okechukwu Obumneme
Chase Peng Yun Ng, Moira Hegyi, Grant Lewison, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan, Mevhibe Hocaoglu